These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 26809011)

  • 1. Treat-to-target in systemic lupus erythematosus: are we there yet?
    Mok CC
    Expert Rev Clin Pharmacol; 2016; 9(5):675-80. PubMed ID: 26809011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treat-to-target in systemic lupus erythematosus: where are we today?
    Mosca M; Boumpas DT; Bruce IN; Cervera R; Czirjak L; Dörner T; Houssiau F; Jacobsen S; Schneider M; Smolen JS; Voskuyl AE; van Vollenhoven RF
    Clin Exp Rheumatol; 2012; 30(4 Suppl 73):S112-5. PubMed ID: 23072706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Treat to target in systemic lupus erythematosus].
    Mucke J; Düsing C; Chehab G; Schneider M
    Z Rheumatol; 2020 May; 79(4):351-358. PubMed ID: 32232548
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treat to target, remission and low disease activity in SLE.
    Morand EF; Mosca M
    Best Pract Res Clin Rheumatol; 2017 Jun; 31(3):342-350. PubMed ID: 29224676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting DORIS Remission and LLDAS in SLE: A Review.
    Parra Sánchez AR; van Vollenhoven RF; Morand EF; Bruce IN; Kandane-Rathnayake R; Weiss G; Tummala R; Al-Mossawi H; Sorrentino A
    Rheumatol Ther; 2023 Dec; 10(6):1459-1477. PubMed ID: 37798595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treat to target in systemic lupus erythematosus: a commentary.
    Ugarte-Gil MF; Burgos PI; Alarcón GS
    Clin Rheumatol; 2016 Aug; 35(8):1903-1907. PubMed ID: 27406378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting lupus low disease activity state and remission in SLE: novel insights.
    Gao D; Hao Y; Fan Y; Ji L; Zhang Z
    Expert Rev Clin Immunol; 2021 Oct; 17(10):1083-1089. PubMed ID: 34392757
    [No Abstract]   [Full Text] [Related]  

  • 8. Value and goals of treat-to-target in systemic lupus erythematosus: knowledge and foresight.
    Doria A; Gatto M; Iaccarino L; Punzi L
    Lupus; 2015 Apr; 24(4-5):507-15. PubMed ID: 25801894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treat-to-target in systemic lupus erythematosus: advancing towards its implementation.
    Parra Sánchez AR; Voskuyl AE; van Vollenhoven RF
    Nat Rev Rheumatol; 2022 Mar; 18(3):146-157. PubMed ID: 35039665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current role of rituximab in systemic lupus erythematosus.
    Mok CC
    Int J Rheum Dis; 2015 Feb; 18(2):154-63. PubMed ID: 25522652
    [TBL] [Abstract][Full Text] [Related]  

  • 11. LUPUS-BEST-treat-to-target in systemic lupus erythematosus: study protocol for a three-armed cluster-randomised trial.
    Mucke J; Kuss O; Brinks R; Schanze S; Schneider M
    Lupus Sci Med; 2021 Jul; 8(1):. PubMed ID: 34253649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treat-to-target in systemic lupus erythematosus: Where are we?
    Ríos-Garcés R; Espinosa G; van Vollenhoven R; Cervera R
    Eur J Intern Med; 2020 Apr; 74():29-34. PubMed ID: 32014364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Outcome measures to be used in clinical trials in systemic lupus erythematosus.
    Strand V; Gladman D; Isenberg D; Petri M; Smolen J; Tugwell P
    J Rheumatol; 1999 Feb; 26(2):490-7. PubMed ID: 9972993
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE.
    Dooley MA; Houssiau F; Aranow C; D'Cruz DP; Askanase A; Roth DA; Zhong ZJ; Cooper S; Freimuth WW; Ginzler EM;
    Lupus; 2013 Jan; 22(1):63-72. PubMed ID: 23263865
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment targets in SLE: remission and low disease activity state.
    Golder V; Tsang-A-Sjoe MWP
    Rheumatology (Oxford); 2020 Dec; 59(Suppl5):v19-v28. PubMed ID: 33280016
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Understanding remission in real-world lupus patients across five European countries.
    Schneider M; Mosca M; Pego-Reigosa JM; Hachulla E; Teh LS; Perna A; Koscielny V; Pike J; Lobosco S; Apolone G
    Lupus; 2016 Apr; 25(5):505-12. PubMed ID: 26635245
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Attaining treat-to-target endpoints with metformin in lupus patients: a pooled analysis.
    Sun F; Zhang D; Wang H; Wang H; Liu Z; Geng S; Wang X; Li T; Wan W; Lu L; Teng X; Morel L; Ye S
    Clin Exp Rheumatol; 2022 Sep; 40(9):1733-1737. PubMed ID: 34874833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PReS-endorsed international childhood lupus T2T task force definition of childhood lupus low disease activity state (cLLDAS).
    Smith EMD; Aggarwal A; Ainsworth J; Al-Abadi E; Avcin T; Bortey L; Burnham J; Ciurtin C; Hedrich CM; Kamphuis S; Lambert L; Levy DM; Lewandowski L; Maxwell N; Morand E; Ozen S; Pain CE; Ravelli A; Saad Magalhaes C; Pilkington C; Schonenberg-Meinema D; Scott C; Tullus K; Beresford MW;
    Clin Immunol; 2023 May; 250():109296. PubMed ID: 36934849
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Treat-to-target in Lupus Nephritis Realistic in Clinical Practice?
    Mok CC
    Curr Rheumatol Rev; 2019; 15(1):2-6. PubMed ID: 29623845
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing remission in systemic lupus erythematosus.
    Mosca M; Bombardieri S
    Clin Exp Rheumatol; 2006; 24(6 Suppl 43):S-99-104. PubMed ID: 17083771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.